AgomAb Therapeutics (NASDAQ:AGMB) Director Purchases 15,000 Shares of Company Stock

AgomAb Therapeutics NV (NASDAQ:AGMB) Director David Epstein bought 15,000 shares of the business’s stock in a transaction dated Thursday, November 5th. The shares were bought at an average cost of $6.90 per share, for a total transaction of $103,500.00. Following the completion of the transaction, the director directly owned 40,000 shares of the company’s stock, valued at $276,000. This trade represents a 60.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

AgomAb Therapeutics Stock Up 1.8%

Shares of NASDAQ AGMB opened at $6.97 on Friday. AgomAb Therapeutics NV has a 12 month low of $6.46 and a 12 month high of $17.82. The business has a fifty day simple moving average of $10.38 and a 200-day simple moving average of $11.88.

AgomAb Therapeutics (NASDAQ:AGMB) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. Equities research analysts forecast that AgomAb Therapeutics NV will post -1.77 EPS for the current year.

Analyst Ratings Changes

Several research analysts have commented on the stock. Piper Sandler started coverage on shares of AgomAb Therapeutics in a report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 target price for the company. Wall Street Zen downgraded shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 27th. B. Riley Financial started coverage on shares of AgomAb Therapeutics in a report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target on the stock. Cantor Fitzgerald began coverage on shares of AgomAb Therapeutics in a research report on Wednesday, August 19th. They issued an “overweight” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday, October 21st. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $37.50.

AgomAb Therapeutics Company Profile

Agomab Therapeutics N.V. is a clinical-stage biotechnology company focused on developing medicines that promote tissue regeneration and address diseases associated with fibrosis and tissue damage. The company’s research is centered on biological pathways involved in repair, remodeling and the disease microenvironment.

Agomab’s lead program is AGMB-129, an orally administered, gut-restricted small-molecule inhibitor of transforming growth factor beta receptor 1, also known as ALK5. The program is being developed for intestinal fibrosis associated with Crohn’s disease, a condition in which scar tissue can narrow the intestine and contribute to complications.

The company also maintains earlier-stage discovery and development programs intended to apply its regenerative medicine expertise to additional gastrointestinal and oncology-related indications.